Clinical Trials
Our Team
Partners
Categories
Blood
Blood Disorder
Breast
CLL
Gastric
Lung
Renal
Skin
Urothelial

Clinical Trials



If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815.730.3098.

Blood

MK 3475-185 : *On Hold* Multiple Myeloma
A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185)

MK 3475-183 : *On Hold* Multiple Myeloma
A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)

IDA-03 : IDA
A phase III, randomized, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators' opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion, P-Monofer-IDA-03

Blood Disorder

Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study

1VIT14039 : Chemo induced Anemia
Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose injection).

Breast

NCT# 02513394 AFT-05, NSABP B-57-I : Adjuvant Breast
Alliance AFT-05: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

SPI-GCF-301 : Chemo induced neutropenia in Breast Cancer
Randomized Trial to Evaluate SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)

CLEE011A2404 : First-Line Breast
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

E2112 NCT 02115282 : Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

A5481082 : Observational: Hormone Receptor Positive Advanced Breast Cancer
POLARIS Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

CLL

ACE-CL-309 : Relapsed or Refactory CLL
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Gastric

EMR100070-007 : Metastatic Gastric
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

Lung

PM1183-C-003-14 : 2nd line limited or extensive stage SCLC
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

NCT 02201992 E4512 : ALK Fusion NSCLC
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT 02488967 GO29527 : Early Stage NSCLC after resection
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PD-L1-SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER

NCT 02193282 CTSU/A081105 : EGFR Mutant NSCLC
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

FKB238-002 AVANA : Non-Squamous NSCLC
A Randomized, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin

NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)

Renal

E7080-G00-307 : Advanced Renal Cell
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma

Skin

E3612 NCT 01950390 : Melanoma
This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery

Urothelial

MK3475-361 : First-Line Advanced or Metastatic Urothelial Cancer
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma



Our Team


President:
Dr. Kulumani M. Sivarajan, MD

Medical Director of Clinical Research:
Dr. Jason Suh, MD

Manager of Clinical Research:
Karen Sceniak, CCRC
ksceniak@jolietoncology.com

Clinical Research Coordinators:
815-730-3098
Maureen Clennon
maureenc@jolietoncology.com

Dipti Tambe
dtambe@jolietoncology.com

Data Manager:
Jennifer Crocker
jennifercrocker@jolietoncology.com

Regulatory Affairs Manager:
Joan Pufahl
joanp@jolietoncology.com

Partners